Atreca Stock Hits 52-Week Low As Initial ATRC-101 Data In Solid Tumor Fails To Impress

Atreca Inc BCEL stock is hovering at a 52-week low after it announced initial data from the dose-escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types.

  • Twenty-six participants were dosed. Eight of the 20 participants (40%) evaluable experienced stable disease (SD), including four with tumor reduction observed. 
  • The remaining 12 participants had progressive disease. 
  • Disease control observed in the study was associated with target expression.
  • Three of six (50%) of participants with evaluable response assessments and baseline tumor H-scores over 50 achieved SD, compared with 1 of 9 (11%) evaluable participants with an H-score below 50.
  • Expansion of peripheral blood CD8+ T cells was observed on day eight following dosing with ATRC-101. 
  • The Company will report additional data from monotherapy dose-expansion cohorts in the Phase 1b trial and combination cohorts with pembrolizumab in 2022.
  • Price Action: BCEL shares are down 34.9% at $5.35 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareMoversTrading IdeasGeneralBriefsSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!